Incyte reports Q2 2021 product revenue $696M (+17% YoY); GAAP net income $149M vs $290M prior year

INCYTE CORP

2020-Q2 EPS reported $0.91 revenue$1,310,427,000

Jakafi net product revenues $529M (+12% YoY); total product and royalty revenues $696M (+17%).
Non-GAAP diluted EPS $0.80 vs $1.24 prior year; GAAP net income $149M down from $290M.
Positive CHMP opinion for tafasitamab in relapsed/refractory DLBCL; Phase 3 vitiligo trials met endpoints.
Updated 2021 guidance: Jakafi revenue tightened to $2,125-$2,170M; SG&A reduced to $725-$755M.
Retifanlimab BLA received FDA complete response letter; MAA still under EMA review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.